- Home
- AYRO vs RNAZ Comparison
AYRO vs RNAZ Comparison
Compare AYRO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- RNAZ
- Stock Information
- Founded
- AYRO 2017
- RNAZ 2016
- Country
- AYRO United States
- RNAZ United States
- Employees
- AYRO N/A
- RNAZ N/A
- Industry
- AYRO Telecommunications Equipment
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- RNAZ Health Care
- Exchange
- AYRO Nasdaq
- RNAZ Nasdaq
- Market Cap
- AYRO 5.8M
- RNAZ 4.9M
- IPO Year
- AYRO N/A
- RNAZ 2021
- Fundamental
- Price
- AYRO $0.76
- RNAZ $3.92
- Analyst Decision
- AYRO
- RNAZ Strong Buy
- Analyst Count
- AYRO 0
- RNAZ 1
- Target Price
- AYRO N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- AYRO 1.5M
- RNAZ 73.3K
- Earning Date
- AYRO 11-14-2024
- RNAZ 11-14-2024
- Dividend Yield
- AYRO N/A
- RNAZ N/A
- EPS Growth
- AYRO N/A
- RNAZ N/A
- EPS
- AYRO N/A
- RNAZ N/A
- Revenue
- AYRO $221,671.00
- RNAZ N/A
- Revenue This Year
- AYRO $2,424.87
- RNAZ N/A
- Revenue Next Year
- AYRO N/A
- RNAZ $233.33
- P/E Ratio
- AYRO N/A
- RNAZ N/A
- Revenue Growth
- AYRO N/A
- RNAZ N/A
- 52 Week Low
- AYRO $0.65
- RNAZ $3.21
- 52 Week High
- AYRO $2.10
- RNAZ $264.00
- Technical
- Relative Strength Index (RSI)
- AYRO 48.69
- RNAZ 23.92
- Support Level
- AYRO $0.65
- RNAZ $6.63
- Resistance Level
- AYRO $0.92
- RNAZ $8.46
- Average True Range (ATR)
- AYRO 0.08
- RNAZ 1.05
- MACD
- AYRO 0.01
- RNAZ -0.22
- Stochastic Oscillator
- AYRO 32.42
- RNAZ 8.04
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.